LET’S WORK TOGETHER TO ADVANCE PSORIASIS LEADERSHIP TOWARDS A WORLD FREE OF PSORIASIS
Your donations help the IPC achieve our vision of a world free of psoriasis . We are a global network of over 100 psoriasis experts, thought leaders, and professionals, dedicated to improving patient care around the globe. We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
You can support the IPC by providing unrestricted funds through our Corporate Membership program or by sponsoring one of our important education, research or patient care initiatives.
For more information on supporting the International Psoriasis Council, please contact Tina Burke, Corporate Relations Director Tina.Burke@psoriasiscouncil.org
Psoriasis News Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis3/31/2020 10:15:00 AMLilly's TALTZ® (IXEKIZUMAB) receives U.S. FDA approval for the treatment of pediatric patients with moderate to severe plaque psoriasis Statement on the Coronavirus (COVID-19) Outbreak3/11/2020 1:09:00 PMFor psoriasis patients diagnosed with COVID-19 disease, the IPC recommends physicians discontinue or postpone use of immunosuppressant medications. This is in accordance with established psoriasis treatment guidelines, which state immunosuppressive psoriasis treatments are contraindicated in patients with active infections. NOW AVAILABLE: IPC's January 2020 Psoriasis Review newsletter2/6/2020 10:54:00 AMJust published - IPC's latest issue of the Psoriasis Review newsletter is now available! This issue features the Top Five Papers in psoriasis research, symposia reports, IPC news, and more! IPC Think Tank 20192/6/2020 More News